Swiss National Bank
CMPX icon

Swiss National Bank’s Compass Therapeutics CMPX Stock Holding History

Swiss National Bank’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376K Sell
171,700
-49,000
-22% -$145K ﹤0.01% 2296
2026
Q1 		$1.17M Buy
+220,700
New +$1.27M ﹤0.01% 2098
2023
Q4 		– Sell
-163,400
Closed -$322K – 2559
2023
Q3 		$322K Hold
163,400
– – ﹤0.01% 2580
2023
Q2 		$520K Hold
163,400
– – ﹤0.01% 2529
2023
Q1 		$534K Buy
+163,400
New +$642K ﹤0.01% 2507

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Swiss National Bank's CMPX Position: Q2 2026 in Review

Swiss National Bank reduced its Compass Therapeutics (CMPX) stake by 22% in Q2 2026, selling an estimated $145K and leaving 171,700 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

Swiss National Bank first reported a position in CMPX in Q1 2023 and has held it in 5 quarters since. The position peaked at $1.17M in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Swiss National Bank held 171,700 shares of Compass Therapeutics worth $376K as of Q2 2026.
  • Swiss National Bank sold 49,000 Compass Therapeutics shares in Q2 2026, an estimated $145K.
  • Compass Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #2296 holding.
  • Swiss National Bank first reported a position in Compass Therapeutics in Q1 2023 and has held it in 5 quarters since.
  • Swiss National Bank's Compass Therapeutics position peaked at $1.17M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.